ADO Price Prediction, page-36

More wild forecasts.

Firstly, the company has already flagged the strong likelihood any results we receive from Doherty will not be comparable to lab results. This is not down ramping or negativity. It is a totally reasonable conclusion based on facts already provided to us by the company.

Secondly, even if the results were a dream come true, there is a strong reluctance to adopt ART. That takes cultural change and while that seems to be happening - extremely slowly - it is not commensurate with the share price doubling virtually overnight. Not even close. You would get a bit of a bump, no more. Money talks right now. Commercial success doubles our share price, not scientific success. That has been the universal pattern of this company for a decade.